Population pharmacokinetics and clinical outcomes of polymyxin B in paediatric patients with multidrug-resistant Gram-negative bacterial infections.

Pei-Le WangPeng LiuQi-Wen ZhangWen-Hua YuanDao WangXiao-Jian ZhangJing Yang

Published in: The Journal of antimicrobial chemotherapy (2022)

Dose adjustment of polymyxin B needs to consider the MIC of infecting pathogens. Current polymyxin B dosing for paediatric patients may be acceptable when MICs are <0.5 mg/L.

Keyphrases

gram negative
multidrug resistant
drug resistant
acinetobacter baumannii
intensive care unit
end stage renal disease
emergency department
klebsiella pneumoniae
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
patient reported outcomes